Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.

Journal of medicinal chemistry - 23 Feb 2023

Tang Xu, Xing Shuaishuai, Ma Mingkang, Xu Ziwei, Guan Qianwen, Chen Yuting, Feng Feng, Liu Wenyuan, Chen Tingkai, Chen Yao, Sun Haopeng

Abstract excerpt

Parkinson's disease (PD) is a progressive neurodegenerative disorder affecting millions of people worldwide. Mutations in the gene encoding leucine-rich repeat kinase 2 (LRRK2) are the most common genetic risk factor for PD. Elevated LRRK2 kinase activity is found in idiopathic and familial PD cases. LRRK2 mutations are involved in multiple PD pathogeneses, including dysregulation of mitochondrial homeostasis,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiparkinson Agents
Share to Leucine-Rich Repeat Serine-Threonine Protein Kinase-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Parkinson Disease

Share to Structure-Activity Relationship

Source

Identifiers

PMID: 36758171
DOI: 10.1021/acs.jmedchem.2c01552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Development and Design Strategy of Leucine-Rich Repeat Kinase 2 Inhibitors: Promising Therapeutic Agents for Parkinson's Disease.PMID 36758171Read ↗

Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.Semantic proximity Read ↗

Recent advances in targeting leucine-rich repeat kinase 2 as a potential strategy for the treatment of Parkinson's disease.Semantic proximity Read ↗

Catalyzing a Cure: Discovery and development of LRRK2 inhibitors for the treatment of Parkinson's disease.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2) inhibitors for Parkinson’s disease: a patent review of the literature to dateSemantic proximity Read ↗

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play.Semantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).Semantic proximity Read ↗

Small Molecule Kinase Inhibitors for LRRK2 and Their Application to Parkinson's Disease ModelsSemantic proximity Read ↗

Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 – 2013)Semantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): an update on the potential therapeutic target for Parkinson’s diseaseSemantic proximity Read ↗

Exploring LRRK2-dependent Mechanisms in Parkinson's Disease Therapy.Semantic proximity Read ↗

Leucine-Rich Repeat Kinase 2 in Parkinson’s Disease: Updated from Pathogenesis to Potential Therapeutic TargetSemantic proximity Read ↗

Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.